( ) stock tumbled late Tuesday despite the computer hardware company reporting fiscal fourth quarter earnings that met expectations and better-than-expected sales. The company's profit guidance was lower than expected. HP said in a news release that it earned an adjusted 93 cents per share on sales of $14.05 billion, up 1.7% year-over-year, for the October-ended quarter. Analysts polled by FactSet projected the Palo Alto, Calif.-based company would post adjusted earnings of 93 cents per share on sales of $13.99 billion. For the same period a year earlier, HP posted adjusted earnings of 90 cents per share on sales of $13.82 billion. "We are pleased with our Q4 performance where we saw revenue growth for the second consecutive quarter, driven by steady progress in Personal Systems and Print," President and CEO Enrique Lores said in a news release. For the current quarter, HP guided for adjusted earnings of 73 cents per share at the midpoint of its range. Analysts were projecting 85 cents per share adjusted earnings for the January-ending quarter, according to FactSet. HP said in a news release that its guidance excludes 13 cents per share "primarily related to restructuring and other charges." On the , HP stock shed more than 7% to 36.09 in recent after-hours action. HP Stock Up 30% This Year Prior to earnings, HP stock fell a half-percent in regular Tuesday trading. Shares have gained 30.4% this year, helped by optimism that AI will help restart following an industry slump in 2022 and . HP's previous July-ended quarter ended a streak of eight quarters where sales declined. Coming into the report, HP stock had an IBD Composite Rating of 55 out of 99, according to . The score combines five separate proprietary ratings into one rating. The best growth stocks have a Composite Rating of 90 or better. Further, HP's IBD Relative Strength Rating was 81 out of 99. The RS Rating means that HP has outperformed 81% of all stocks in IBD's database over the past year. HP stock broke out above a 39.52 consolidation pattern buy point on Monday but closed below that level Tuesday, according to .
Report: Iowa CB Jermari Harris opts out of rest of seasonNew law for using ID in shops and supermarkets next year
NEW YORK (AP) — U.S. stock indexes drifted lower Tuesday in the runup to the highlight of the week for the market, the latest update on inflation that’s coming on Wednesday. The S&P 500 dipped 0.3%, a day after pulling back from its latest all-time high . They’re the first back-to-back losses for the index in nearly a month, as momentum slows following a big rally that has it on track for one of its best years of the millennium . The Dow Jones Industrial Average fell 154 points, or 0.3%, and the Nasdaq composite slipped 0.3%. Tech titan Oracle dragged on the market and sank 6.7% after reporting growth for the latest quarter that fell just short of analysts’ expectations. It was one of the heaviest weights on the S&P 500, even though CEO Safra Catz said the company saw record demand related to artificial-intelligence technology for its cloud infrastructure business, which trains generative AI models. AI has been a big source of growth that’s helped many companies’ stock prices skyrocket. Oracle’s stock had already leaped more than 80% for the year coming into Tuesday, which raised the bar of expectations for its profit report. In the bond market, Treasury yields ticked higher ahead of Wednesday’s report on the inflation that U.S. consumers are feeling. Economists expect it to show similar increases as the month before. Wednesday’s update and a report on Thursday about inflation at the wholesale level will be the final big pieces of data the Federal Reserve will get before its meeting next week, where many investors expect the year’s third cut to interest rates . The Fed has been easing its main interest rate from a two-decade high since September to take pressure off the slowing jobs market, after bringing inflation nearly down to its 2% target. Lower rates would help give support to the economy, but they could also provide more fuel for inflation. Expectations for a series of cuts through next year have been a big reason the S&P 500 has set so many records this year. Trading in the options market suggests traders aren’t expecting a very big move for U.S. stocks following Wednesday’s report, according to strategists at Barclays. But a reading far off expectations in either direction could quickly change that. The yield on the 10-year Treasury rose to 4.22% from 4.20% late Monday. Even though the Fed has been cutting its main interest rate, mortgage rates have been more stubborn to stay high and have been volatile since the autumn. That has hampered the housing industry, and homebuilder Toll Brothers’ stock fell 6.9% even though it delivered profit and revenue for the latest quarter that topped analysts’ expectations. CEO Douglas Yearley Jr. said the luxury builder has been seeing strong demand since the start of its fiscal year six weeks ago, an encouraging signal as it approaches the beginning of the spring selling season in mid-January. Elsewhere on Wall Street, Alaska Air Group soared 13.2% after raising its forecast for profit in the current quarter. The airline said demand for flying around the holidays has been stronger than expected. It also approved a plan to buy back up to $1 billion of its stock, along with new service from Seattle to Tokyo and Seoul . Boeing climbed 4.5% after saying it’s resuming production of its bestselling plane , the 737 Max, for the first time since 33,000 workers began a seven-week strike that ended in early November. Vail Resorts rose 2.5% after the ski resort operator reported a smaller first-quarter loss than analysts expected in what is traditionally its worst quarter. All told, the S&P 500 fell 17.94 points to 6,034.91. The Dow dipped 154.10 to 44,247.83, and the Nasdaq composite slipped 49.45 to 19,687.24. In stock markets abroad, indexes were mixed in China after the world’s second-largest economy said its exports rose by less than expected in November. Stocks rose 0.6% in Shanghai but fell 0.5% in Hong Kong. Indexes fell across much of Europe ahead of a meeting this week by the European Central Bank, where the widespread expectation is for another cut in interest rates. AP Business Writers Matt Ott and Elaine Kurtenbach contributed.LEXINGTON, Va. — The Middlebury field hockey team scored twice in the second half and held off a strong Tufts' squad to capture the NCAA Championship with a 2-1 triumph. The Panthers secured their seventh-straight crown and ninth overall as the program finishes the season with a 19-2 mark. Middlebury manufactured a great opportunity on the first penalty corner with 5:49 elapsed. Grace Keefe blasted a rising shot off an insert that Tufts goalie Lydia Eastburn deflected away with her blocker. The Jumbos countered at the 6:36 mark as Claire Gavin took a redirection off a Panther stick and raced toward the left side of the cage. Goalie Madeline DiLemme thwarted Gavin's backhanded attempt to keep the score 0-0. The Panthers had two final chances in the opening quarter off penalty corner inserts from Caroline Segal. Each shot attempt from Emily Stone (9:39) and Megan Fuqua (14:32) was blocked by Jumbo defenders as the score read 0-0 after one. Middlebury continued its relentless pressure just 50 seconds into the second stanza. Georgianne Defeo grabbed possession in a group of Jumbos and Panthers and blasted a bid toward the left post that was stopped by Eastburn. Lilly Branka nearly put the Panthers ahead at the 18:18 mark by sliding around two Tufts defenders on the endline and launching a bid near the left post. Eastburn stood her ground, pinning herself to the post and knocking the bid away. Lainie Person looked to put the Jumbos on the board just 2:04 into the second half, but her bid sailed wide left. Middlebury took the lead with 2:10 left on its first shot of the second half. Branka dribbled the ball near the Tufts endline and flicked a pass toward the middle of the cage. Segal sprawled out and tapped the ball in while diving to the ground for the 1-0 edge. The Panthers extended their lead at the 50:44 mark. Claire McMichael ran down the right side of the field and slid a pass toward the middle of the circle. Eastburn came off her line to kick the ball away, but Defeo got to the ball a second earlier and poked it underneath Eastburn's pads to make it 2-0. Tufts responded 22 seconds later off a penalty corner. Kylie Rosenquest found the cage after a great pass from Pearson to cut the deficit to one with 8:54 showing on the clock. Tufts tried to muster up some momentum, but Middlebury's defense stepped up to the task, not allowing a single shot over the remainder of action to earn the 2-1 triumph. Branka was named the NCAA Tournament's Most Outstanding Player after tallying two assists during the playoffs. Branka also earned a spot on the all-tournament squad alongside Amy Griffin (2G, 2A), Keefe (1G, 1A) and Segal (6G, 1A). With one goal today, Segal moves into fifth all-time in single-season points (57). Her tally is her fifth game-winner this season and the 10th of her career. Segal's marker caps her season with 24 goals, which is tied for fifth in program history over one campaign. The Panthers close the season with 105 goals scored, good for second all-time behind the 107 scored by the 2022 and 2023 National Championship teams. Tufts and Middlebury battled for the 35th time and the fourth time in the NCAA Tournament. The Panthers have won each of the last two meetings in the postseason, including a 2-0 victory in the 2018 title tilt. Middlebury made its 21st postseason appearance and played in the championship game for the 13th time. This marked the fifth time that the NCAA Championship took place between a pair of NESCAC squads. The Panthers have appeared in each of those five contests, claiming three of them. Middlebury caps the season with a 19-2 record, marking the 13th-consecutive season that the program has tallied 15 or more triumphs.
Mid-inclination orbit provides more SAR-imaging opportunities at middle latitudes of the globe for ICEYE customers. HELSINKI, Finland , Dec. 21, 2024 /PRNewswire/ -- ICEYE, the global leader in SAR satellite operations for Earth Observation and persistent monitoring, announced today that it has launched two new satellites to its constellation of SAR satellites. Both satellites expand the availability of ICEYE's latest imaging technology to deliver additional 25 cm imaging capacity. The satellites were integrated via Exolaunch and launched as part of the Bandwagon-2 rideshare mission with SpaceX from Vandenberg Space Force Base in California, USA . Both satellites have established communication, and early routine operations are underway. With today's launch, ICEYE has successfully launched 40 satellites into orbit since 2018, with nine satellites launched in 2024 alone. The new SAR satellites were launched into mid-inclination orbits; compared to a polar orbit, these mid-inclination orbits provide more than twice the collection opportunities at middle latitudes of the globe. ICEYE customers have many areas of interest in these middle latitudes (+/- 45 degrees), and these customers will benefit from increased persistence over these regions. Customers with imaging interests outside these middle latitudes will continue to benefit from the frequent revisit enabled by ICEYE's dozens of satellites in polar orbits. ICEYE's unique mix of mid-inclination and polar orbits provides its customers with deep revisit capabilities for targets all around the globe. The new satellites will serve ICEYE's commercial missions as part of the world's largest SAR satellite constellation owned and operated by ICEYE. Rafal Modrzewski , CEO and Co-founder of ICEYE said: "This launch marks another significant milestone in ICEYE's ability to provide our customers with a rich diversity of collection opportunities. We bolster our industry-leading SAR constellation and expand our customers' collection opportunities in the areas most important to them." Today's launch is another step forward in ICEYE's steady drumbeat of innovative breakthroughs in Earth Observation. This year alone, ICEYE has, for example, introduced Dwell Precise, a new 25 cm imaging mode that offers its customers the highest-fidelity 25cm imaging capability, and adds advanced capability to ICEYE's line of Dwell products; launched an API that allows customers to directly task its SAR satellite constellation; and launched ICEYE Ocean Vision to provide actionable intelligence for maritime domain awareness. About ICEYE ICEYE delivers unparalleled persistent monitoring capabilities to detect and respond to changes in any location on Earth, faster and more accurately than ever before. Owning the world's largest synthetic aperture radar (SAR) satellite constellation, ICEYE provides objective, near real-time insights, ensuring that customers have unmatched access to actionable high-quality data, day or night, even in challenging environmental conditions. As a trusted partner to governments and commercial industries, ICEYE delivers intelligence in sectors such as insurance, natural catastrophe response and recovery, security, maritime monitoring, and finance, enabling decision-making that contributes to community resilience and sustainable development. ICEYE operates internationally with offices in Finland , Poland , Spain , the UK, Australia , Japan , UAE, Greece , and the US. We have more than 700 employees, inspired by the shared vision of improving life on Earth by becoming the global source of truth in Earth Observation. Media contact: press@iceye.com Visit www.iceye.com and follow ICEYE on LinkedIn and X for the latest updates and insights. View original content to download multimedia: https://www.prnewswire.com/news-releases/iceye-expands-its-earth-observation-capabilities-with-launch-of-two-sar-satellites-for-mid-inclination-orbit-on-the-bandwagon-2-mission-with-spacex-302337876.html SOURCE ICEYENone
Sparks scores 20 off the bench, Ball State knocks off Evansville 80-43
Unai Emery knows Champions League top-eight spot is possible for Aston VillaEvaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including alpha- and Auger-emitting radioconjugates into Phase 1 solid tumor studies FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic modalities to target cancers. Due to recent communications with the U.S. Food and Drug Administration (FDA, or the Agency) regarding a confirmatory study to support accelerated approval and the regulatory submission for iopofosine I 131, the Company has decided to pursue strategic options for the further development and commercialization of this product candidate. The CLOVER-WaM study was conducted in accordance with earlier FDA communications from an end of Phase 2 meeting and from a meeting in early 2024, during which the Company was informed that positive results for major response rate (MRR) as the primary endpoint could be acceptable to support accelerated approval of iopofosine I 131 as a treatment for Waldenstrom’s macroglobulinemia (WM). Based upon a recent Type-C meeting with the FDA, the Company now believes that a submission seeking accelerated approval would need to be based on the MRR data from CLOVER-WaM and enrollment in a randomized, controlled confirmatory study that is designed to generate data on progression-free survival (PFS). “While iopofosine I 131’s positive WM data along with the high unmet medical need for these patients support further investment, we have determined that such a program may best be brought to market by a larger organization with greater resources. Importantly, partnering or divesting this program supports our commitment to providing this potentially life-saving drug to the patients who need it as quickly as possible,” stated James Caruso, president and CEO of Cellectar. “We believe iopofosine I 131 represents a compelling opportunity as it has shown strong efficacy and good tolerability based on our clinical studies. Moreover, the commercial work we conducted demonstrates iopofosine I 131’s substantial market opportunity based upon the product profile, which includes off-the-shelf global distribution, orphan pricing and existing unmet medical need.” Cellectar remains confident in the potential of its phospholipid ether drug conjugate platform and the targeted radiotherapies in its development pipeline. Iopofosine I 131’s clinical success validates the platform’s ability to target cancers and Cellectar will leverage its experience to focus on the development of its earlier clinical programs. Specifically, Cellectar will focus on those assets it believes have the highest therapeutic potential and opportunity for value creation. As highlighted by recent acquisitions and collaborations within the radiopharmaceutical sector, precision isotopes like alpha- and Auger-emitters have emerged as the leading therapeutics of interest. Consequently, the Company will now focus its resources on targeting solid tumors by advancing CLR 121225, its actinium-225 based program, and CLR 121125, its iodine-125 Auger-emitting program into the clinic. Cellectar expects to file Investigational New Drug applications in the first half of 2025 for both CLR-121225 and CLR-121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers. Both programs have demonstrated robust in vivo activity, tolerability, excellent targeting and uptake in preclinical solid tumor models. The Company believes this approach will provide an expedited timeframe to achieve safety and proof-of-concept data in patients. The Company’s strategic reprioritization will impact all departments and result in an immediate reduction in headcount of approximately 60%, which should be complete by the end of the fourth quarter 2024. The Company anticipates that the implementation of the restructuring will extend its cash runway into the third quarter of 2025. “We are being methodical in our efforts to reorganize the company with the goal of conserving cash while maintaining the flexibility to execute immediate priorities and build for long-term growth and value creation. This reorganization is difficult but necessary for the future growth potential of Cellectar,” said Mr. Caruso. “I want to extend my deepest gratitude to our departing employees for their significant contributions to our work and their dedication to making a difference in the lives of patients.” About Cellectar Biosciences, Inc. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug ConjugateTM (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset, iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer, CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. In addition, iopofosine I 131 is under evaluation in Phase 2b studies for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, alongside the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 Orphan Drug and Fast Track Designations for various cancer indications. New data from the CLOVER-WaM Phase 2 clinical trial were recently presented in an oral presentation at the 66th American Society of Hematology Annual Meeting and Exposition (ASH 2024). For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook. Forward-Looking Statement Disclaimer This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to obtain regulatory exclusivities, the availability of priority review vouchers, our ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2023, and our Form 10-Q for the quarter ended September 30, 2024. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements. Contacts MEDIA: Christy Maginn Bliss Bio Health 703-297-7194 cmaginn@blissbiohealth.com INVESTORS: Anne Marie Fields Precision AQ 212-362-1200 annemarie.fields@precisionaq.com
Building an investment portfolio worth $1 million or more is a dream many people share, yet relatively few will achieve. In fact, when asked what a "high net worth" looks like in a 2023 survey by Empower, the median response was $400,000 -- and 74% of survey participants believed they'd never reach that threshold. Investing in the stock market is one of the most attainable ways to generate serious wealth, and you don't need to be an expert at choosing stocks or timing the market. Sometimes, all it takes is one investment that can transform your finances. Exchange-traded funds (ETFs) are bundles of securities grouped into a single investment, often containing dozens or even hundreds of stocks. Investing in just one share of an ETF, then, can allow you to gain exposure to a wide variety of stocks at once with minimal effort. While not all ETFs are strong investments (and what you choose to buy will depend heavily on your risk tolerance and overall goals), there's one fund that could potentially turn $300 per month into $1.2 million or more over time. A growth fund with built-in protection Many investors of all experience levels buy ETFs based on the S&P 500 ( ^GSPC 1.09% ) . These funds contain slices of every company within the benchmark index . The S&P 500 is reserved for only the strongest and largest companies in the U.S., and most of these businesses are industry-leading juggernauts -- ranging from tech giants like Apple and Amazon to longstanding brands like Coca-Cola and 3M . While investing in an S&P 500 ETF can be a wise choice, if you're looking to supercharge your potential earnings, a growth fund like the Vanguard S&P 500 Growth ETF ( VOOG 1.18% ) could be an even better option. This ETF contains only the fastest-growing companies within the S&P 500. There are a total of 234 stocks in the fund, with close to half of them coming from the technology industry. The three largest holdings are Apple, Nvidia , and Microsoft , which collectively make up roughly 35% of the entire fund. The Vanguard S&P 500 Growth ETF can be a wise choice if you're looking to balance risk and reward. Because all of the stocks in this fund are also in the S&P 500, they have a strong track record and are more likely to survive market turbulence. However, they're also more likely to earn above-average returns over time. Building a $1.2 million portfolio There are never any guarantees with any investment, and growth funds, in particular, can carry more risk. While these particular growth stocks are among the strongest out there, many fast-growing companies will still experience intense volatility -- especially in the short term. That said, if you're willing to ride out any stock market storms for the chance to earn above-average returns, a growth ETF could be a fantastic option. VOOG data by YCharts Over the past 10 years, the Vanguard S&P 500 Growth ETF has earned an average rate of return of 14.95% per year, as of this writing. The Vanguard S&P 500 ETF , by comparison, has seen an average return of just 13.30% per year in that time. It's unclear whether this growth ETF will continue earning these types of returns going forward, so it's wise to keep your expectations in check and assume you might see lower earnings in the future. For simplicity's sake, let's assume you could earn either 13%, 14%, or 15% average annual returns. (While the fund has only been around since 2010, it earned an annualized return of roughly 12.6% from its inception through the bottom of the most recent bear market.) If you're investing $300 per month, here's approximately how those contributions could add up over time: Number of Years Total Portfolio Value: 13% Avg. Annual Return Total Portfolio Value: 14% Avg. Annual Return Total Portfolio Value: 15% Avg. Annual Return 20 $291,000 $328,000 $369,000 25 $560,000 $655,000 $766,000 30 $1,056,000 $1,284,000 $1,565,000 Data source: Author's calculations via investor.gov. To reach $1.2 million in total savings, you'd need to invest consistently for around 30 years while earning a 14% average annual return -- slightly less than what the Vanguard S&P 500 Growth ETF has achieved over the last decade. Even if this ETF earns much lower returns going forward, you could still earn a lot of money over time. Say, for example, you only earn 8% average annual returns -- which is lower than the market's historic average of around 10% per year . With $300 per month, you could still accumulate around $400,000 after 30 years. While that's far less than $1 million, it's still a life-changing amount of wealth for most people. If you're putting off investing because you're worried about earning below-average returns, you could be missing out on serious gains. The right investment can supercharge your savings, and ETFs require next to no effort on your part other than investing consistently. By keeping a long-term outlook and choosing the right investment, you could earn more than you might think in the stock market.NEW YORK , Dec. 10, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of PACS Group Inc. (NYSE: PACS) of (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") in connection with the Company's April 11, 2024 initial public offering ("IPO"); (ii) securities between April 11, 2024 and November 5, 2024 , both dates inclusive (the "Class Period"); and/or (iii) common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's September 2024 secondary public offering ("SPO"), of the important January 13, 2025 lead plaintiff deadline. So what: If you purchased PACS common stock pursuant and/or traceable to the IPO and/or securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the PACS class action, go to https://rosenlegal.com/submit-form/?case_id=30617 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 13, 2025 . A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, the Registration Statement and defendants made false and/or misleading statements and/or failed to disclose that: (1) PACS engaged in a "scheme" to submit false Medicare claims which "drove more than 100% of PACS' operating and net income from 2020 – 2023"; (2) PACS engaged in a "scheme" to "bill thousands of unnecessary respiratory and sensory integration therapies to Medicare"; (3) PACS engaged in a scheme to falsify documentation related to licensure and staffing; and (4) as a result of the foregoing, defendants' positive statements about PACS' business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the PACS class action, go to https://rosenlegal.com/submit-form/?case_id=30617 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View original content to download multimedia: https://www.prnewswire.com/news-releases/pacs-investors-have-opportunity-to-lead-pacs-group-inc-securities-fraud-lawsuit-302328029.html SOURCE THE ROSEN LAW FIRM, P. A.
Prairie premiers urge action on security to fend off Trump's tariff threatsNone
NoneTess Daly enjoyed a glamorous Christmas night out with her 20-year-old daughter, Phoebe, and fans can't get over how alike they look. The mother-daughter duo dazzled as they posed for photos, showing off their chic outfits and radiant smiles. Tess, 55, went all out for the evening, donning a halterneck top adorned with sparkling gold sequins. She paired the festive top with classic black trousers, hoop earrings, and her signature blonde waves styled to perfection. Phoebe stuns in elegant evening wear Phoebe complemented her mum's look in a sophisticated black ballgown featuring a crossover design with stylish cut-out detailing. Like Tess, she wore her blonde locks in soft waves and opted for smokey eye makeup paired with a nude lip. The 20-year-old shared the adorable mirror selfie on her social media, captioning it: "All smiles always with mama." Fans were quick to flood the comments section with compliments, with one writing: "Stunners," while another added: "You look so alike!" A close-knit family This festive outing is just one example of Tess and Phoebe's strong bond . The family, which includes Tess's husband Vernon Kay and their younger daughter Amber, often share glimpses of their life together in their stunning six-bedroom home. Vernon recently opened up about their Christmas traditions, revealing how much they enjoy spending time as a family. He told The Sun: "We’re all actually really looking forward to sitting around and playing games this Christmas." Tess Daly sparkles as she parties with ultra-glam daughter Phoebe, 20 Tess Daly's final Strictly look is everything we were hoping for Tess Daly's daily diet revealed - and it's so relatable Family fun and festive traditions Vernon shared how technology plays a big role in their holiday celebrations. “One of the games we play on the Xbox is called Drawful, and it’s a modern take on Pictionary,” he said. The proud dad also highlighted the importance of balancing digital activities with outdoor pursuits. “Phoebe has taken up golf, which is a joy for me,” he added. “We really encourage the kids to get outside and stay active.” An emotional moment for Tess on Strictly Earlier this month, Tess was overcome with emotion during the Strictly Come Dancing semi-final. After professional dancer Dianne Buswell made a heartfelt speech about her celebrity partner Chris McCausland, Tess was visibly moved. Dianne praised Chris, who lost his sight at 22, for embracing the spirit of the competition despite the challenges he faced. She said: “I have taught Chris all this time without a single visual cue. He’s never been able to watch a video back or see his competitors, yet he has captured the spirit of the show.” As the camera cut to Tess, she was seen fighting back tears, a touching reminder of how much Strictly means to those involved. A stylish pair Tess and Phoebe’s festive outing was a celebration of family, fashion, and the holiday spirit. Their dazzling looks and close bond left fans in awe, with many commenting on their striking resemblance. As the family prepares to celebrate Christmas in their beautiful home, one thing is clear: the Dalys know how to balance glamour with heartfelt traditions. Whether it’s a glittering night out or cosy games at home, their bond shines through.